AtriCure
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 4 days.
- Recent price momentum is +41.6% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 9.6% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 08:27 UTC
Data coverage: 5 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation F
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 178.7x | Better than 2% |
| Forward P/E | 207.5x | Better than 1% |
| Price / Sales | 4.9x | Better than 23% |
| P/E vs own 5-yr range | 94th pctl | Better than 10% |
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability C
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 75.0% | Better than 87% |
| Operating margin | -1.8% | Better than 19% |
| Net margin | -2.1% | Better than 23% |
| Return on equity | -2.4% | Better than 25% |
| Return on invested capital | -1.9% | Better than 26% |
Momentum A+
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | 13.1% | Better than 93% |
| 6-month return | 95.8% | Better than 99% |
| 12-month return (ex latest month) | 63.0% | Better than 88% |
| Distance below 52-week high | 16.1% | Better than 68% |
Financial Health B
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 4.0x | Better than 81% |
| Debt to assets | 11.2% | Better than 67% |
| Interest coverage | -0.7x | Better than 23% |
Analyst View C+
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 75.0% | Better than 51% |
| Upside to average target | 19.2% | Better than 31% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 54.11
- Open
- 54.03
- Day range
- 54.03 - 56.19
- Avg price
- 55.38
- Volume
- 813.13K
- Turnover
- 45.03M
- Turnover ratei
- 1.66%
- Volume ratioi
- 1.24
- Amplitudei
- 3.99%
- 52-week rangei
- 25.36 - 66.02
Valuation
- P/Ei
- -230.79
- P/E (TTM)i
- 178.68
- P/Bi
- 5.29
- EPSi
- -0.24
- Book value / shi
- 10.47
- Net profit
- -12.22M
- Net assets
- 533.21M
Share structure
- Market cap
- 2.82B
- Float capi
- 2.71B
- Shares out
- 50.92M
- Float sharesi
- 48.88M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 1970-01-01
16.1% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-23.42M net over the window
Short interest
- Shares short
- 4.89M
- % of floati
- 9.61%
- Days to coveri
- 7.60
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of AtriCure (ATRC)?
AtriCure last traded at 55.39. This page shows a periodic quote snapshot. Check the displayed quote time.
What is AtriCure's market cap?
About 2.82B.
What is the P/E ratio of AtriCure?
The trailing twelve-month P/E is 178.68. The Valuation tab shows it against the stock's own five-year range.
Does AtriCure pay a dividend?
AtriCure does not currently pay a regular dividend.
Is AtriCure a buy according to analysts?
The consensus of 8 analysts is a Buy rating, with an average 12-month price target of 66.00, which implies 19.2% upside from the current price. This is not investment advice.
What is AtriCure's StockVane Quant Rating?
The StockVane Momentum strategy currently rates AtriCure a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
AtriCure discussion 0 comments